Approximately a third of frontotemporal dementia (FTD) is genetic with mutations in three genes accounting for most of the inheritance: C9orf72, GRN, and MAPT. Impaired synaptic health is a common mechanism in all three genetic variants, so developing fluid biomarkers of this process could be useful as a readout of cellular dysfunction within therapeutic trials.
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia / Sogorb-Esteve A., Nilsson J., Swift I.J., Heller C., Bocchetta M., Russell L.L., Peakman G., Convery R.S., van Swieten J.C., Seelaar H., Borroni B., Galimberti D., Sanchez-Valle R., Laforce R., Jr., Moreno F., Synofzik M., Graff C., Masellis M., Tartaglia M.C., Rowe J.B., Vandenberghe R., Finger E., Tagliavini F., Santana I., Butler C.R., Ducharme S., Gerhard A., Danek A., Levin J., Otto M., Sorbi S., Le Ber I., Pasquier F., Gobom J., Brinkmalm A., Blennow K., Zetterberg H., Rohrer J.D., Nelson A., Bouzigues A., Greaves C.V., Cash D., Thomas D.L., Todd E., Benotmane H., Nicholas J., Samra K., Shafei R., Timberlake C., Cope T., Rittman T., Benussi A., Premi E., Gasparotti R., Archetti S., Gazzina S., Cantoni V., Arighi A., Fenoglio C., Scarpini E., Fumagalli G., Borracci V., Rossi G., Giaccone G., Di Fede G., Caroppo P., Tiraboschi P., Prioni S., Redaelli V., Tang-Wai D., Rogaeva E., Castelo-Branco M., Freedman M., Keren R., Black S., Mitchell S., Shoesmith C., Bartha R., Rademakers R., Poos J., Papma J.M., Giannini L., van Minkelen R., Pijnenburg Y., Nacmias B., Ferrari C., Polito C., Lombardi G., Bessi V., Veldsman M., Andersson C., Thonberg H., Öijerstedt L., Jelic V., Thompson P., Langheinrich T., Lladó A., Antonell A., Olives J., Balasa M., Bargalló N., Borrego-Ecija S., de Mendonça A., Verdelho A., Maruta C., Ferreira C.B., Miltenberger G., do Couto F.S., Gabilondo A., Gorostidi A., Villanua J., Cañada M., Tainta M., Zulaica M., Barandiaran M., Alves P., Bender B., Wilke C., Graf L., Vogels A., Vandenbulcke M., Van Damme P., Bruffaerts R., Poesen K., Rosa-Neto P., Gauthier S., Camuzat A., Brice A., Bertrand A., Funkiewiez A., Rinaldi D., Saracino D., Colliot O., Sayah S., Prix C., Wlasich E., Wagemann O., Loosli S., Schönecker S., Hoegen T., Lombardi J., Anderl-Straub S., Rollin A., Kuchcinski G., Bertoux M., Lebouvier T., Deramecourt V., Santiago B., Duro D., Leitão M.J., Almeida M.R., Tábuas-Pereira M., Afonso S.. - In: ALZHEIMER'S RESEARCH & THERAPY. - ISSN 1758-9193. - ELETTRONICO. - 14:(2022), pp. 14.118-14.130. [10.1186/s13195-022-01042-3]
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia
Sorbi S.;Cantoni V.;Nacmias B.;Ferrari C.;Polito C.;Lombardi G.;Bessi V.;
2022
Abstract
Approximately a third of frontotemporal dementia (FTD) is genetic with mutations in three genes accounting for most of the inheritance: C9orf72, GRN, and MAPT. Impaired synaptic health is a common mechanism in all three genetic variants, so developing fluid biomarkers of this process could be useful as a readout of cellular dysfunction within therapeutic trials.File | Dimensione | Formato | |
---|---|---|---|
alzh res therapy 2022.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
2.18 MB
Formato
Adobe PDF
|
2.18 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.